Key result
Persistent or new LVH linked to ~120% higher major CV risk versus LVH regression.
Why the study?
LVH in hypertensive patients increases cardiovascular risk, but the prognostic implication of LVH regression following antihypertensive therapy has not been clearly investigated.
Does LVH regression after antihypertensive therapy reduce cardiovascular events in patients with hypertension?
Population
837 hypertensive patients with LVH at diagnosis
Comparison
LVH regression vs persistent or newly developed LVH
Design
Cohort study
Follow-up
Median, 50.4 months
Authors
Loading...
Supports LVH regression as a prognostic marker in treated hypertension; leaves open whether targeting it improves outcomes.
Cohort (n=1,872)
Yes
Does LVH regression after antihypertensive therapy reduce cardiovascular events in patients with hypertension?
Effect estimate: HR 2.203 (95% CI 1.374-3.532)
p-value: p=0.001
LVH regression in hypertensive patients is associated with a reduction in cardiovascular events, highlighting its utility as a prognostic marker.
Kim et al. (2022) conducted a cohort in Hypertension (n=1,872). LVH regression vs. Persistent or newly developed LVH was evaluated on Composite of cardiovascular death, hospitalization for heart failure, coronary revascularization, stroke, and aortic events (HR 2.203, 95% CI 1.374-3.532, p=0.001). Persistent or newly developed left ventricular hypertrophy during antihypertensive therapy was associated with a significantly higher risk of composite cardiovascular events compared to LVH regression (HR 2.203).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: